Synchrocyclotron for the MEVION S250i Proton Therapy System Delivered to Huntsman Cancer Institute

Mevion Medical Systems announced today that it has delivered the synchrocyclotron accelerator for the MEVION S250i Proton Therapy System® to Huntsman Cancer Institute (HCI) at the University of Utah (U of U) on March 28, 2020. The 15-ton accelerator, the world’s smallest, was driven up the side of the Red Butte Canyon and was lowered by a crane into the proton facility the same day.

“With the arrival of the accelerator, we are on track to provide proton therapy to our patients later this year,” said Dennis Shrieve, M.D, Ph.D., radiation oncologist at HCI and professor and chair of radiation oncology at the U of U.

The system, now under installation, features Mevion’s industry-leading HYPERSCAN® Pencil Beam Scanning (PBS) technology. HYPERSCAN improves on existing scanning capabilities to deliver more conformal fields of therapeutic radiation to tumors faster, with more precision and is the most advanced pencil beam scanning available. HCI, Utah’s only National Cancer Institute-designated Comprehensive Cancer Center, has been closely tracking and considering proton therapy for over a decade. Recent technological advances by Mevion made it the right time to add this powerful cancer-fighting tool to their cancer center. HCI will also integrate* Siemen’s SOMATOM® Definition Edge CT on rails to provide precise image-guided proton therapy (IGPT).

“Proton therapy is especially effective in delivering targeted radiation while preserving healthy tissues. Patients with tumors close to critical organs along with pediatric cancer patients can benefit the most from this advanced treatment,” said Bill Salter, Ph.D., director of radiation oncology at HCI and professor and chief of the division of medical physics at the U of U. “The HYPERSCAN system will be a powerful new addition to Huntsman Cancer Institute’s already formidable suite of treatment tools.”

By reducing the size and complexity of a proton therapy system, Mevion has allowed hospitals to offer proton therapy without the enormous expenditures and space requirements needed by other single-room or multi-room proton systems. Today, more cancer centers are considering providing compact proton therapy to their patients because of the technology Mevion has advanced.

“We are honored to provide Utah with the first proton therapy center in the Mountain West,” said Tina Yu, Ph.D., chief executive officer of Mevion Medical Systems. “HCI is a nationally recognized research center and treatment hospital and we look forward to building our partnership to advance the science and application of proton therapy.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”